Celcuity (NASDAQ:CELC – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Other equities research analysts have also issued research reports about the stock. HC Wainwright dropped their price objective on shares of Celcuity from $155.00 to $150.00 and set a “buy” rating for the company in a research report on Monday, November 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Needham & Company LLC decreased their price target on shares of Celcuity from $140.00 to $134.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. Guggenheim began coverage on shares of Celcuity in a research report on Friday, November 6th. They set a “buy” rating and a $169.00 price target for the company. Finally, Citigroup reiterated a “market outperform” rating on shares of Celcuity in a report on Monday, November 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $151.79.
Get Our Latest Stock Report on CELC
Celcuity Price Performance
CELC stock opened at $64.37 on Friday. The company has a 50 day moving average price of $72.47 and a two-hundred day moving average price of $98.23. The company has a debt-to-equity ratio of 6.04, a quick ratio of 14.59 and a current ratio of 14.62. The stock has a market capitalization of $3.16 billion, a P/E ratio of -13.67 and a beta of 0.16. Celcuity has a one year low of $53.54 and a one year high of $151.02.
Celcuity (NASDAQ:CELC – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.30. As a group, sell-side analysts expect that Celcuity will post -5.01 EPS for the current year.
Institutional Investors Weigh In On Celcuity
Hedge funds and other institutional investors have recently modified their holdings of the stock. Entropy Technologies LP bought a new stake in shares of Celcuity in the 3rd quarter valued at approximately $2,044,000. Apis Capital Advisors LLC raised its position in shares of Celcuity by 5.4% during the 3rd quarter. Apis Capital Advisors LLC now owns 567,200 shares of the company’s stock valued at $45,104,000 after acquiring an additional 29,200 shares in the last quarter. FORA Capital LLC bought a new position in Celcuity during the third quarter worth $698,000. Teachers Retirement System of The State of Kentucky lifted its stake in Celcuity by 39.9% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 17,729 shares of the company’s stock worth $1,410,000 after purchasing an additional 5,053 shares during the last quarter. Finally, ACT Capital Partners L.P. bought a new position in Celcuity during the third quarter worth $4,664,000. Institutional investors own 63.33% of the company’s stock.
Celcuity Company Profile
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
See Also
- Five stocks we like better than Celcuity
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
